Stay updated on SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial
Sign up to get notified when there's something new on the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page.
Latest updates to the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check13 days agoChange DetectedThe results of the Phase II trial on sequential pembrolizumab and radiotherapy for locally advanced NSCLC with high PD-L1 expression have been posted, detailing efficacy and safety outcomes, including progression-free survival and overall survival rates.SummaryDifference39%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe website has added new features, while several detailed data fields and options for downloading study information in various formats have been removed.SummaryDifference4%
- Check43 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference4%
- Check50 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.1%
- Check57 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential improvements or features.SummaryDifference0.2%
Stay in the know with updates to SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page.